Richard D. Peterson Acquires 7,000 Shares of Sienna Biopharm (SNNA) Stock

Sienna Biopharm (NASDAQ:SNNA) CFO Richard D. Peterson purchased 7,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average price of $15.00 per share, for a total transaction of $105,000.00. Following the completion of the purchase, the chief financial officer now owns 7,000 shares in the company, valued at $105,000. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Sienna Biopharm (NASDAQ:SNNA) traded up 1.73% during trading on Friday, reaching $19.38. The company had a trading volume of 76,768 shares. Sienna Biopharm has a 1-year low of $18.50 and a 1-year high of $21.20.

ILLEGAL ACTIVITY NOTICE: “Richard D. Peterson Acquires 7,000 Shares of Sienna Biopharm (SNNA) Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/08/19/sienna-biopharmaceuticals-inc-snna-cfo-richard-d-peterson-buys-7000-shares-updated-updated.html.

About Sienna Biopharm

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

What are top analysts saying about Sienna Biopharm? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sienna Biopharm and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit